Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.80B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 0.57M
Average 0.71M
ZYME Net Income
Bottom-line profit after all expenses, interest, and taxes.
Zymeworks Inc.NASDAQ: ZYME
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income turns positive
Q3 FY2026 net income was $173.7M, compared with -$19.6M a year earlier. Trailing-twelve-month net income was $43.31M.
Context
- Net income amounted to 76.6% of revenue in FY2025, down 84.2 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of $105.26M (+229.7%) for the fiscal year ending Dec 2026, a step up from the +33.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $173.7M+485.8% QoQ
- Last fiscal yearDec 2025
- -$81.13M+33.9% YoY
- LTMSep 2026
- $43.31M+168.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +986.1% | +195.9% | -790.3 pp |
| 1 year | +33.9% | +229.7% | +195.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (81.13M) USD
- Year-over-year change
- +33.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (81.13M) | +33.9% |
| FY2024 | 2024-12-31 | (122.7M) | -3.4% |
| FY2023 | 2023-12-31 | (118.67M) | -195.4% |
| FY2022 | 2022-12-31 | 124.34M | +158.7% |
| FY2021 | 2021-12-31 | (211.84M) | — |
Net Income vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 net income of $43.31M is the 2nd highest of the 11 companies compared; the peer median is -$112.93M.
- Its year-over-year change of +168.3% is the 3rd highest of 11, against a peer median of -8.7%.
- Net income amounts to 16.3% of revenue for ZYME, versus a peer median of 161.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $294.88M | +220.5% | — | 42.0% | |
| LTM Sep 2026 | $43.31M | +168.3% | — | 16.3% | |
| LTM Mar 2026 | $34.86M | +346.4% | — | 48.0% | |
| LTM Mar 2026 | -$59.14M | -242.2% | — | 166.4% | |
| LTM Mar 2026 | -$70.36M | -26.1% | — | 44.8% | |
| LTM Mar 2026 | -$88.87M | +31.7% | — | — | |
| LTM Mar 2026 | -$136.99M | +8.6% | — | 173.0% | |
| LTM Mar 2026 | -$162.08M | -206.2% | — | 1363.9% | |
| LTM Jun 2026 | -$163.33M | +8.8% | — | 155.6% | |
| LTM Sep 2026 | -$282.65M | -26.9% | — | — | |
| LTM Sep 2026 | -$309.11M | -37.7% | — | 275986.6% | |
| Peer median (excluding ZYME) | -$112.93M | -8.7% | — | 161.0% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Cost of Revenue | 0 | 0 | 142.99M | 0 | 0 |
| Gross Profit | 26.68M | 412.48M | (66.98M) | 76.3M | 105.97M |
| Gross Margin | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% |
| Research & Development | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| Selling, General & Admin | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M |
| Operating Expenses | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| EBITDA | (206.09M) | 142.49M | (120.7M) | (108.62M) | (68.64M) |
| EBITDA Margin | -772.4% | 34.5% | -158.8% | -142.4% | -64.8% |
| Operating Income | (215.63M) | 130.53M | (138.05M) | (137.11M) | (92.54M) |
| Operating Margin | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Interest Income | 1.97M | 3.6M | 19.71M | 19.94M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M |
| Income Before Tax | (212.36M) | 135.23M | (119.24M) | (116.61M) | (79.75M) |
| Pre-Tax Margin | -795.9% | 32.8% | -156.9% | -152.8% | -75.3% |
| Income Tax Expense | (516K) | 10.89M | (568K) | 6.08M | 1.38M |
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Net Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| EPS (Basic) | (4.06) | 1.91 | (1.72) | (1.62) | (1.08) |
| EPS (Diluted) | (4.61) | 1.90 | (1.72) | (1.62) | (1.08) |
| Weighted Avg Shares | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M |
| Weighted Avg Shares (Diluted) | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$25.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.